EC
YMAB

EntryPoint Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

EntryPoint Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,654
Closed -$56.1K – 845
2025
Q1 		$56.1K Buy
+12,654
New +$73.5K 0.03% 642
2024
Q4 		– Sell
-17,071
Closed -$224K – 996
2024
Q3 		$224K Buy
17,071
+10,919
+177% +$138K 0.13% 395
2024
Q2 		$74.3K Buy
+6,152
New +$83.1K 0.11% 428
2024
Q1 		– Sell
-41,949
Closed -$286K – 1805
2023
Q4 		$286K Buy
+41,949
New +$243K 0.27% 29

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

EntryPoint Capital's YMAB Position: Q2 2025 in Review

EntryPoint Capital sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 12,654 shares — an estimated $56.1K sold.

EntryPoint Capital first reported a position in YMAB in Q4 2023 and held it in 4 quarters. The position peaked at $286K in Q4 2023. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • EntryPoint Capital reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EntryPoint Capital sold 12,654 Y-mAbs Therapeutics shares in Q2 2025, an estimated $56.1K.
  • EntryPoint Capital first reported a position in Y-mAbs Therapeutics in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Y-mAbs Therapeutics position peaked at $286K in Q4 2023.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.